The R3 Medical Warning Letter Is a Pattern, Not a Mood
FDA's August 14, 2026 warning letter to R3 Medical Companies repeats a pattern seen across regenerative clinic letters: claims that drive drug and biologic classification, failed 1271.10(a) criteria, sterile-manufacturing CGMP gaps, exosome labels that may not match the process, and a link back to a 2019 untitled letter. Operators can check their own files against each element.
Exosome, stem cell and extracellular vesicle products discussed here are not approved by the FDA for any indication. This essay describes regulatory and public records. It does not describe an available treatment, and it is not legal advice.
Abstract
Reviews public FDA correspondence on regenerative clinics as patterned documents rather than isolated events. Identifies the repeating elements in warning and untitled letters and how operators can check their own files against them. Notes FDA's 2019 statement that no exosome products are FDA approved.
Indexed in OpenAlex under author A5139488776.
What is the difference between an FDA warning letter and an untitled letter?
Are FDA warning letters public?
Why did FDA say the products did not qualify as 361 HCT/Ps?
What CGMP gaps recur in regenerative medicine warning letters?
How should a clinic use a warning letter as a diligence checklist?
Sources
- FDA Warning Letter CBER 26-726330, R3 Medical Companies, Aug 14, 2026
- FDA untitled letter to R3 Stem Cell, LLC, May 28, 2019 (FDA untitled letters database, CBER)
- 21 CFR 1271.10(a)
- 21 CFR Part 211 (sections 211.22, 211.42, 211.100, 211.113, 211.160, 211.166) and 21 CFR 210.3(b)(12)
- FDA Public Safety Notification on Exosome Products, Dec 6, 2019
All publications · Andrew J. Hillman · LinkedIn · Book a meeting